Ipamorelin: the mechanism, the data, and where each comparison stops

Before the details

Here is the ipamorelin research in plain terms. The body makes its own growth hormone (GH) in pulses, mostly at night. Ipamorelin is a lab-made peptide that pushes one of those pulses by hitting the same cell receptor that the natural hunger hormone, ghrelin, uses. What made it notable in 1998 was precision: it raised GH without dragging up cortisol or prolactin, the way older peptides did. The numbers that hold up are small and specific — a roughly two-hour half-life in people, a single GH pulse about 40 minutes after a dose, and dose-dependent bone growth in rats. The one human efficacy trial failed. Most of what you read online about "ipamorelin CJC-1295" stacks comes from the pharmacology of each peptide separately, not from a trial of the two together. Below, each finding is pinned to its study.

Mechanism: selective GH release

Ipamorelin activates GHS-R1a — the growth-hormone-secretagogue receptor type 1a, which is the ghrelin receptor — on pituitary somatotrophs (the GH-making cells). Receptor activation runs through the Gq/PLC pathway, raises intracellular calcium, and releases GH. The defining result: in primary rat pituitary cells, anaesthetised rats, and conscious swine, ipamorelin released GH as potently as GHRP-6 (swine ED50 = 2.3 nmol/kg vs 3.9 nmol/kg), yet did not raise ACTH or cortisol above the GHRH baseline even above 200-fold its GH ED50 ^[1]. That dissociation — strong GH, flat stress hormones — is the selectivity that names the compound.

The mechanism is distinct from, and complementary to, GHRH (growth-hormone-releasing hormone), which works through a separate cAMP pathway. That complementarity is the pharmacological basis for combining ipamorelin with a GHRH analog. In ovine pituitary cells, GHRH + GHRP-2 together raised GH mRNA, GHS-R, GHRH-R, and Pit-1 expression, and GHRP-2 suppressed both somatostatin-receptor subtypes while GHRH raised only one ^[8] — a molecular account of why a GHRP and a GHRH analog amplify each other. A broader review confirms this synergy is a class-wide property: GHRPs stay partly active under conditions (glucose, free fatty acids, somatostatin) that nearly abolish GHRH alone ^[9]. The neuroendocrine circuit basis — ghrelin co-localizing with GHRH and inhibiting somatostatin — is laid out in a 2021 review ^[11].

What is ipamorelin peptide

Ipamorelin peptide is a wholly synthetic pentapeptide — five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 (molecular formula C38H49N9O5, ~711.9 Da, CAS 170851-70-4). It is not a natural human peptide; it mimics ghrelin's action at GHS-R1a. The design is deliberate: the alpha-aminoisobutyric acid at position 1 and the D-amino acids confer resistance to enzymatic breakdown, and the molecule was derived from GHRP-1 by removing a central dipeptide ^[1]. It was the first growth-hormone secretagogue characterized as highly GH-selective, which is the property that distinguishes "ipamorelin peptide" from the broader GHRP family.

Human pharmacokinetics

Population PK/PD modeling in healthy male volunteers (n=8 per dose; five 15-minute IV infusions of 4.21-140.45 nmol/kg) showed dose-proportional, linear kinetics: terminal half-life approximately 2 hours, clearance 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg, and a single GH pulse peaking near 0.67 h (40 minutes) after dosing ^[2]. This is one of the only human ipamorelin datasets in existence and the source of the half-life figure that propagates everywhere. It is detailed on the half-life page.

The one human efficacy trial

The only published Phase 2 RCT (NCT00672074) enrolled 114 adults undergoing bowel resection, dosed 0.03 mg/kg IV twice daily for up to 7 days, and measured time to first tolerated meal. It missed: 25.3 h with ipamorelin vs 32.6 h placebo, p=0.15 ^[3]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm vs 94.8% of placebo — no ipamorelin-specific safety signal in that short perioperative window, but also no demonstrated efficacy. This is the defining human anchor for ipamorelin, and it is a negative one.

Preclinical efficacy and the recent record

In adult female Sprague-Dawley rats, subcutaneous ipamorelin at 18, 90, and 450 μg/day (divided three times daily for 15 days) raised longitudinal bone-growth rate dose-dependently from 42 μm/day (vehicle) to 44, 50, and 52 μm/day — with no change in total IGF-1, IGFBPs, or bone-turnover markers, pointing to a partly local, GH-pulse-driven skeletal effect ^[4]. In streptozotocin-diabetic mice, IV ipamorelin produced greater GH hypersecretion (150 ± 35 µg/L) than non-diabetic controls (62 ± 11 µg/L), alongside hepatic GH-receptor resistance and suppressed IGF-I — altered pharmacodynamics in a diabetic state ^[7]. The most recent in-vivo study (2024 ferret cachexia model) found intraperitoneal ipamorelin (1-3 mg/kg) inhibited cisplatin-induced weight loss by ~24% in the delayed phase, but had no anti-emetic effect on either acute or delayed emesis ^[5]. Recent narrative reviews (2026) place ipamorelin as an investigational GH-axis secretagogue with preclinical musculoskeletal signals and explicitly flag the absence of rigorous human trials and the potential for serious harm ^[16][18].

Ipamorelin cjc-1295

Ipamorelin cjc-1295 is the most-searched pairing in this space. CJC-1295 is a GHRH analog; ipamorelin is a GHRP. They act on two different receptors through two different pathways, and the rationale for combining them is the complementary mechanism documented above ^[8][9][11]. A 2026 orthopaedic narrative review reports that CJC-1295 + ipamorelin improved maximum tetanic muscle tension in a murine glucocorticoid-induced muscle-loss model — while stating that the evidence is limited to animal studies ^[15]. There is no trial of the combination for any human outcome. Every claim about the stack is an extrapolation from each agent's separate single-agent pharmacology, not a tested combined result.

Ipamorelin vs sermorelin

Ipamorelin vs sermorelin is a comparison across two drug classes, not two versions of the same thing. Sermorelin is a GHRH analog (GHRH 1-29) that acts on the GHRH receptor; ipamorelin is a ghrelin-receptor (GHS-R1a) agonist ^[1]. They raise GH by separate, complementary mechanisms — which is exactly why GHRH analogs and GHRPs are studied together rather than as substitutes ^[9][11]. Ipamorelin's distinguishing feature within its own class is selectivity: GH release without the cortisol and prolactin bump seen with other GHRPs ^[1]. A head-to-head human efficacy comparison of the two compounds is not part of the published record.

Ipamorelin vs tesamorelin

Ipamorelin vs tesamorelin is, again, GHRP versus GHRH analog. Tesamorelin is a stabilized GHRH analog acting on the GHRH receptor; ipamorelin acts on the ghrelin receptor ^[1]. The mechanistic relationship is complementary, not competitive — the two receptor systems converge on GH but enter through different doors ^[8][11]. The published ipamorelin literature does not include a direct comparative trial against tesamorelin; what exists is the separate single-agent pharmacology of each, summarized in the class reviews ^[9][11].